This has been exemplified in a colorectal cancer (CRC) immunotherapy model, where treatment with CX-5461, either alone or in combination with anti-PD-1 antibodies, resulted in higher levels of CD3+, CD4+, and activated cytotoxic T lymphocytes (CTLs), alongside a reduction in myeloid-derived suppressor cells (MDSCs) within the murine spleen [79]. The gene discussed is CD4; the disease is colorectal carcinoma.